Drug Profile
Research programme: eye disorders therapeutic - Dios/Avid Bioservices
Alternative Names: DS101Latest Information Update: 11 Jan 2018
Price :
$50
*
At a glance
- Originator Dios Therapeutics
- Developer Dios Therapeutics; Peregrine Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
- 06 Jun 2007 Preclinical trials in Eye disorders in USA (Parenteral)